Solid Tumor Trials :: Val-083 Clinical Trials

About Kintara Therapeutics
Additional Resources
Healthcare Professionals
- Study of VAL-083 in Patients With MGMT Unmethylated, Bevacizumab-naive Recurrent Glioblastoma Recruiting
- Safety Study of VAL-083 and Radiotherapy in Patients With Newly Diagnosed GBM Having Unmethylated MGMT Expression Active, not recruiting

Solid Tumor Trials

A Multi-center Study of VAL-083 in Patients With Recurrent Platinum Resistant Ovarian Cancer

Withdrawn

This is an open label, multi-center, Phase 1/2 clinical trial in subjects with recurrent

More Information

Enrollment

For more information on enrollment into the current VAL-083 trial, please contact us or visit clinicaltrials.gov for location information.

The safety and efficacy of the investigational use of this product has not been determined. There is no guarantee that the investigational use listed will be filed with and/or approved for marketing by a regulatory agency.